New clinical program aims to address gaps in cystic fibrosis care

For patients with cystic fibrosis (CF) — a life-shortening, genetic condition that causes damage to the lungs and other organs — navigating a fragmented health system, complicated by costly therapies and knowledge barriers, can be challenging.

That’s why Prime Therapeutics/Magellan Rx (Prime/MRx) is proud to share the latest clinical offering from GuidedHealth^®. This new program encourages providers to prescribe CF medicines to patients with no record of treatment. Other similar GuidedHealth programs are offered for diabetes, rheumatoid arthritis, multiple sclerosis and hepatitis C.

If left untreated, CF can cause permanent lung damage and perhaps lead to respiratory distress or failure as well as lung infections and/or collapse, pancreas inflammation, infertility, liver disease or other complications. Closing the gap with appropriate treatment can improve a patient’s medical condition and prevent future complications.

“At Prime/MRx, we are thrilled to collaborate with clients to develop programs that close treatment gaps and offer the kind of care we’d want for our loved ones,” said Steve Heavrin, senior director of Health Insurance Marketplace (HIM) at Prime/MRx. “Our team is committed to helping members effectively manage their medications throughout their treatment journey.”

GuidedHealth is a comprehensive suite of programs that address underuse, overuse, drug safety and preferred use of medications. Through the analysis of available pharmacy and medical data, GuidedHealth provides actionable, clinical intelligence to prescribers, members and plans to help guide members to effective medication use throughout their health care journey. These insights result in improved care, safer medicine use, better health outcomes and lower overall cost of care.